Floatz logo

FLUTICASONE

Myelodysplastic/Myeloproliferative Diseases

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Myelodysplastic/Myeloproliferative Diseases cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Romidepsin
Jacqueline Garcia, MD
Phase 2/3BBB
Busulphan
Jacqueline Garcia, MD
Phase 2/3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Anti-Thymoglobulin, Rabbit
M.D. Anderson Cancer Center
Phase 2/3BBB

View all 31 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →